

Mission:

To protect, promote & improve the health of all people in Florida through integrated state, county & community efforts.



Ron DeSantis
Governor

Joseph A. Ladapo, MD, PhD
State Surgeon General

Vision: To be the **Healthiest State** in the Nation

Important Information for Health Care Practitioners Regarding COVID-19

December 16, 2021

Early treatment of COVID-19 saves lives. Health care practitioners should use their clinical judgment when recommending treatment options for patients' individualized health care needs. This may include emerging treatment options with appropriate patient informed consent or enrollment in a clinical trial.

Current Authorized COVID-19 Outpatient Therapeutics

Monoclonal Antibodies (MABs) for Pre-Exposure Prophylaxis

- Evusheld (tixagevimab co-packaged and administered together with cilgavimab; intramuscular injection)

MABs for Post-Exposure Prophylaxis

- *Bamlanivimab plus etesevimab (Intravenous (IV) infusion)*
- *Casirivimab plus imdevimab (IV infusion or subcutaneous (SQ) injection)*
- *Sotrovimab (IV infusion)*

MABs for Early Treatment of COVID-19

- *Bamlanivimab plus etesevimab (IV infusion)*
- *Casirivimab plus imdevimab (IV infusion or SQ injection)*
- *Sotrovimab (IV infusion)*

Resources and FDA EUA Links

[Bamlanivimab plus etesevimab](#)

[Casirivimab plus imdevimab](#)

[Sotrovimab](#)

[Evusheld](#)

[Treatment Guidelines](#)

COVID-19 Treatments Pending FDA Approval

In November 2021, Merck released [study results](#) about an oral antiviral drug to treat COVID-19. The Antimicrobial Drugs Advisory Committee to the Food and Drug Administration (FDA) recommended emergency use authorization (EUA) for molnupiravir. FDA approval is pending.

In December 2021, Pfizer released [study results](#) for their oral antiviral treatment called Paxlovid. Pfizer has submitted its data, and FDA approval is pending.

Emerging Treatment Options for COVID-19

Fluvoxamine

Recent evidence shows a potential therapeutic role of fluvoxamine (administered orally) for COVID-19. See these links for more information: [JAMA Network](#); [Lancet Global Health](#)

Budesonide

Recent evidence shows a potential therapeutic role of budesonide (an inhaled glucocorticoid) for COVID-19. See these links for more information: [The Lancet](#); [The Lancet Respiratory Medicine](#)

In addition to the drugs discussed above, there are several investigational agents in clinical trials and/or pending submission of relevant data to the FDA for review. See these links for more information: [RAPS](#); [COVID-19 Treatment Guidelines](#); [Greenelab](#); [Stanford Univ Database](#); [Medscape](#)